A retrospective cohort study on 459 pregnant patients, performed by Voicu et al. [33], investigated the interrelationship between thrombophilia (protein C, antithrombin III, protein S, homocysteine, factor V Leiden, MTHFR, factor XIII and prothrombin G20210A gene mutations) and adverse pregnancy events, established a 60.37-fold risk of FGR in pregnant patients with antithrombin deficiency and an 11.69-fold risk of FGR in pregnant patients with prothrombin gene mutation compared to the control group (p < 0.05). The gene discussed is MTHFR; the disease is thrombophilia.